Orexo has been granted a patent for a method to combat opioid dependence in individuals misusing alcohol. The method involves administering an opioid agonist while managing alcohol consumption through a self-directed digital cognitive behavioral therapy program, potentially in the form of a mobile medical application. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating opioid dependence with alcohol consumption
A recently granted patent (Publication Number: US11986472B1) outlines a method for treating opioid dependence in patients who are also consuming alcohol. The method involves administering a sublingual dose of buprenorphine and naloxone to manage withdrawal symptoms and cravings for opioids. Additionally, patients engage with a self-directed digital, interactive cognitive behavioral therapy program aimed at reducing alcohol consumption. This dual approach aims to not only address opioid dependence but also decrease alcohol consumption, ultimately increasing patient adherence to the treatment regimen.
The self-directed digital therapy program mentioned in the patent comprises various modules utilizing different psychotherapeutic approaches, such as addressing drinking patterns, alcohol craving control, coping with risky situations, and preventing relapse. The sublingual dose of buprenorphine and naloxone ranges from 0.7 mg to 11.4 mg of buprenorphine and 0.18 mg to 2.9 mg of naloxone once daily. Patients diagnosed with alcohol use disorder can benefit from this method, which allows for engagement with the therapy program before, during, or after the administration of the medication. The temporal overlap between therapy engagement and medication administration is also highlighted as a key aspect of the treatment approach outlined in the patent.
To know more about GlobalData’s detailed insights on Orexo, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
